Genmab A/S (GNMSF.PK) announced that the US Food and Drug Administration has granted Fast Track designation for daratumumab. This designation covers patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD) or are double refractory to a PI and an IMiD.
In August 2012, Genmab granted Janssen Biotech, Inc. an exclusive worldwide license to develop and commercialize daratumumab.
Click here to receive FREE breaking news email alerts for Genmab A/S and others in your portfolio
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org